AGAsensio Gonzalez

Asensio Gonzalez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Asensio Gonzalez has a total of 112 co-authors. Here are the top co-authors by number of shared publications:

  • Edmond J. Walsh

    Department of Engineering Science, University of Oxford, OX1 3PJ, UK

    5 shared publications
  • Ronan Grimes

    Stokes Institute, University of Limerick, Limerick, Ireland

    5 shared publications
  • Jacob D. Mulligan

    Department of Medicine, University of Wisconsin, Madison, WI 53706, USA.

    4 shared publications
  • Pere Clavé

    Gastrointestinal Physiology Laboratory, Department of Surgery, CIBERehd CSdM-UAB, Hospital Universitari de Mataró, Consorci Sanitari del Maresme, Universitat Autònoma de Barcelona, Carretera de Cirera 230, 08304, Mataró (Barcelona), Spain.

    4 shared publications
  • Albert Urwyler

    From the Department for Anesthesia, Interdisciplinary Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital (AG, TG, SD-K, AU, OB) and Basel Institute for Clinical Epidemiology and Biostatistics, University of Basel, Basel, Switzerland (SD-K)

    3 shared publications
  • Ashley J. Davis

    3 shared publications

Latest Publications

  • BMI and malignant hyperthermia pathogenic ryanodine receptor type 1 sequence variants in Switzerland

    by Asensio Gonzalez, Thierry Girard, Salome Dell-Kuster, Albert Urwyler, Oliver Bandschapp

    BACKGROUND: Ryanodine receptor type 1 (RYR1) sequence variants are pathogenic for malignant hyperthermia. Variant carriers have a subtle increase in resting myoplasmic calcium concentration compared with nonaffected individuals, but whether this has metabolic effects in daily life is unknown. OBJECTIVES: We analysed the potential effect of malignant hyperthermia-pathogenic RYR1 sequence variants on BMI as a single factor. Due to the heterogeneity of genetic variants predisposing to malignant hyperthermia, and to incomplete information about their regional distribution, we describe the prevalence of RYR1 variants in our population. DESIGN: A retrospective cohort study. SETTING: A single University hospital. PATIENTS: Patients from malignant hyperthermia families with pathogenic RYR1 sequence variants were selected if BMI was available. OUTCOME MEASURES: BMI values were compared amongst malignant hyperthermia susceptible (MHS) and malignant hyperthermia-negative individuals using hierarchical multivariable analyses adjusted for age and sex and considering family clustering. Variant prevalence was calculated. RESULTS: The study included 281 individuals from 42 unrelated malignant hyperthermia families, 109 of whom were MHS and carriers of the familial RYR1 sequence variants. Median [IQR] BMI in MHS individuals with pathogenic RYR1 variants was 22.5 kg m−2 [21.3 to 25.6 kg m−2]. In malignant hyperthermia-negative individuals without variants, median BMI was 23.4 kg m−2 [21.0 to 26.3 kg m−2]. Using multivariable regression adjusted for age and sex, the mean difference was −0.73 (95% CI −1.51 to 0.05). No carrier of a pathogenic RYR1 sequence variant was found to have BMI higher than 30 kg m−2. Only 10 RYR1 variants from the list of the European MH Group were found in our cohort, the most common being p.Val2168Met (39% of families), p.Arg2336His (24%) and p.Arg614Cys (12%). CONCLUSION: The observed tendency towards lower BMI values in carriers of malignant hyperthermia-pathogenic RYR1 sequence variants points to a possible protective effect on obesity. This study confirms regional differences of the prevalence of malignant hyperthermia-pathogenic RYR1 sequence variants, with just three variants covering 75% of Swiss MHS families. TRIAL REGISTRATION: This manuscript is based on a retrospective analysis.


  • Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency

    by Soledad Levano, Asensio Gonzalez, Martine Singer, Philippe Demougin, Henrik Rüffert, Albert Urwyler, Thierry Girard


  • Protection From Varicella Zoster in Solid Organ Transplant Recipients Carrying Killer Cell Immunoglobulin-Like Receptor B Haplotypes

    by Laurent Schmied, Grzegorz Terszowski, Asensio Gonzalez, Karin Schmitter, Hans H. Hirsch, Christian Garzoni, Christian van Delden, Katia Boggian, Nicolas J. Mueller, Christoph Berger, et al.

    Natural killer cell function is regulated by inhibitory and activating killer cell immunoglobulin-like receptors (KIR). Previous studies have documented associations of KIR genotype with the risk of cytomegalovirus (CMV) replication after solid organ transplantation. In this study of 649 solid organ transplant recipients, followed prospectively for infectious disease events within the Swiss Transplant Cohort Study, we were interested to see if KIR genotype associated with virus infections other than CMV. We found that KIR B haplotypes (which have previously been linked to protection from CMV replication) were associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95% confidence interval, 0.21-0.91; P = 0.03). No significant associations were detected regarding the risk of herpes simplex, Epstein-Barr virus or BK polyomavirus infections. In conclusion, these data provide evidence that the relative protection of KIR haplotype B from viral replication after solid organ transplantation may extend beyond CMV to other herpes viruses, such as varicella zoster virus and possibly Epstein-Barr virus.


  • Open Access

    Preferential allele amplification leading to RyR1 misgenotyping in a malignant hyperthermia susceptible individual

    by Asensio Gonzalez, Martine Singer, Christoph Noppen, Albert Urwyler, Thierry Girard

  • KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients

    by A Gonzalez, K Schmitter, H H Hirsch, C Garzoni, C van Delden, K Boggian, N J Mueller, C Berger, J Villard, O Manuel, et al.

    Previous studies have associated activating Killer cell Immunoglobulin-like Receptor (KIR) genes with protection from cytomegalovirus (CMV) replication after organ transplantation. Whether KIR-associated protection is operating in the context of primary infection, re-activation, or both, remains unknown. Here we correlated KIR genotype and CMV serostatus at the time of transplantation with rates of CMV viremia in 517 heart (n=57), kidney (n=223), liver (n=165) or lung (n=72) allograft recipients reported to the Swiss Transplant Cohort Study. Across the entire cohort we found B haplotypes—which in contrast to A haplotypes may contain multiple activating KIR genes—to be protective in the most immunosuppressed patients (receiving anti-thymocyte globulin induction and intensive maintenance immunosuppression) (hazard ratio after adjustment for covariates 0.46, 95% confidence interval 0.29–0.75, P=0.002). Notably, a significant protection was detected only in recipients who were CMV-seropositive at the time of transplantation (HR 0.45, 95% CI 0.26–0.77, P=0.004), but not in CMV seronegative recipients (HR 0.59, 95% CI 0.22–1.53, P=0.28). These data indicate a prominent role for KIR—and presumably natural killer (NK) cells—in the control of CMV replication in CMV seropositive organ transplant recipients treated with intense immunosuppression.


  • Open Access

    A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs

    by K Czaja, A-S Borer, L Schmied, G Terszowski, M Stern, A Gonzalez

    Analysis of killer cell immunoglobulin-like receptor (KIR) expression has been notoriously difficult because of the cross-reactivity of available antibodies, in particular between activating and inhibitory isoforms. We undertook a comprehensive study of available anti-KIR antibodies binding to activating KIRs (a-KIRs). Using cell lines stably transfected with a-KIRs (KIR2DS1–S5 and KIR3DS1), we confirmed documented binding specificities. In addition, we show that clones HPMA4 and 143211—previously assumed to be specific for KIR2DS1/L1 and KIR2DL1, respectively—bind KIR2DS5 and KIR2DS3 (HPMA4), and KIR2DS5 (143211). Other antibodies with previously undocumented binding were JJC11.6 (recognizing KIR2DS3) and 5.133 (recognizing all a-KIRs except KIR2DS1 and KIR2DS3). The novel KIR2DS5 reactivities were confirmed by blocking with soluble KIR-Fc fusion proteins, and by reverse transcriptase-PCR analysis of sorted primary natural killer cells. In conclusion, we show formerly undocumented binding properties of anti-KIR antibodies. These cross-reactivities should be taken into account when analyzing KIR expression.


  • Open Access

    Modulation of the natural killer cell KIR repertoire by cytomegalovirus infection

    by Hojjatollah N. Charoudeh, Grzegorz Terszowski, Karol Czaja, Asensio Gonzalez, Karin Schmitter, Martin Stern

    Patients carrying activating killer cell immunoglobulin‐like receptor (KIR) genes are significantly protected from CMV‐associated complications after solid organ or hematopoietic stem cell transplantation. Whether previous infection with CMV affects NK‐cell function in healthy donors is unknown. We studied the KIR repertoire and alterations of KIR expression after in vitro exposure to CMV in 54 healthy donors. The expression of neither activating nor inhibitory KIRs was different at baseline between 23 seropositive and 31 seronegative donors. However, after co‐culture of NK cells with CMV‐infected fibroblast cells, expression of the inhibitory receptors KIR2DL1 and KIR2DL3 and the activating receptor KIR3DS1 significantly increased in CMV‐seropositive donors. In CMV‐seronegative donors, changes were subtle and restricted to the subset of NK cells expressing NK‐cell group antigen 2C (NKG2C). Expansion of inhibitory KIRs occurred exclusively in donors carrying the cognate HLA class I ligands, whereas the presence of the putative ligand HLA‐Bw4 was not necessary for the expansion of KIR3DS1‐expressing NK cells. Our data show that previous infection with CMV does not alter the resting NK‐cell receptor repertoire, but appears to modify how NK cells respond to re‐exposure to CMV in vitro.


  • Antibodies against Carbonic Anhydrase in Patients with Aplastic Anemia

    by Jan Lakota, Annika Lanz, Maria Dubrovcakova, Barbora Jankovicova, Asensio Gonzalez, Martin Stern

    Background/Aims: Antibodies against carbonic anhydrase (CA) have been detected in patients with an aplastic anemia (AA)-like syndrome after autologous stem cell transplantation. Methods: We analyzed sera of 53 bona fide AA patients before and after treatment with anti-thymocyte globulin (ATG) or bone marrow transplantation for the presence of anti-CA antibodies. Results: Anti-CA antibodies were detected in 20 patients (38%) and were associated with older age at diagnosis of AA. Antibody-positive patients showed poor response to ATG treatment (complete response 14%) and inferior long-term survival (36% at 10 years), when compared to antibody-negative patients (complete response and 10-year survival both 64%). Two thirds of patients with antibodies at diagnosis of AA became antibody negative after treatment with ATG. Clearance of the antibody did not appear to be associated with hematological improvement. Conclusion: Antibodies against CA are detected frequently at diagnosis of AA, and their presence identifies a subset of patients with poor response to immunosuppressive treatment.


  • Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells

    by Hojjatollah Nozad Charoudeh, Laurent Schmied, Asensio Gonzalez, Grzegorz Terszowski, Karol Czaja, Karin Schmitter, Laura Infanti, Andreas Buser, Martin Stern

    Natural killer (NK) cells require interaction of inhibitory surface receptors with human leukocyte antigen (HLA) ligands during development to acquire functional competence in a process termed “licensing.” The quantity of HLA required for this process is unknown. Two polymorphisms affecting HLA-C surface expression (rs9264942 and rs67384697) have recently been identified, and shown to influence progression of HIV infection. We typed a cohort of healthy donors for the two HLA-C-related polymorphisms, KIR2DL1 and KIR2DL3, and their respective HLA-C ligands and analyzed how HLA ligands influenced licensing status of killer cell immunoglobulin-like receptor (KIR)+ NK cells in terms of degranulation and cytokine production in response to HLA-deficient target cells. The presence of respective HLA class I ligands increased the function of KIR2DL1+ and KIR2DL3+ NK cells in a dose-dependent manner. In contrast, neither of the HLA-C-related polymorphisms nor the quantity of cell surface HLA-C had any significant effect on NK cell function. Interestingly, HLA-Cw7—an HLA-C allele with low surface expression—licensed KIR2DL3+ NK cells more strongly than any other KIR2DL3 ligand. The quantity of cell surface HLA-C does not appear to influence licensing of NK cells, and the HLA-C-related polymorphisms presumably influence HIV progression through factors unrelated to NK cell education.